Intranasal Narcan NDA Submitted for Opioid Overdose
Adapt Pharma announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Narcan (naloxone) Nasal Spray for the treatment of opioid overdose.
Currently all FDA-approved formulations of naloxone are injectable. The intranasal form will present as a new easy-to-use formulation of naloxone to be available in community settings.
Narcan Nasal Spray was developed in collaboration with the National Institutes on Drug Abuse (NIDA). In February 2015, the FDA granted Fast Track designation to Narcan Nasal Spray.
For more information visit AdaptPharma.com.